Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Wilms Tumor 1Sarcoma, Synovial 1Rhabdomyosarcoma 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pleuropulmonary blastoma 1Neurofibrosarcoma 1Neuroblastoma 1Leukemia, Myeloid, Acute 1Leukemia 1Hematologic Neoplasms 1Blastic Plasmacytoid Dendritic Cell Neoplasm 1

Interventions

Cyclophosphamide 5venetoclax 3tagraxofusp 3fludarabine phosphate 3Whole-Body Irradiation 3Thiotepa 3Mycophenolic Acid 3Methotrexate 3merphos 2Tacrolimus 2Cyclosporins 2Cyclosporine 2prednylidene 1lorvotuzumab mertansine 1fludarabine 1exifone 1dexamethasone acetate 1dexamethasone 21-phosphate 1deltacortene 1azathiopurine 1auricularum 1X-Rays 1Vincristine 1Specimen Handling 1Sirolimus 1Rituximab 1Prednisone 1Peripheral Blood Stem Cell Transplantation 1Nivolumab 1Methylprednisolone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Blastic Plasmacytoid Dendritic Cell Neoplasm × lorvotuzumab mertansine × Clear all
NCT02420873 2018-08-28

An Open-label Phase II Study of Lorvotuzumab Mertansine

M.D. Anderson Cancer Center

Phase 2 Completed
9 enrolled 7 charts
LymphoidMyeloidOther hematologic neoplasm

Blastic Plasmacytoid Dendritic Cell Neoplasm, Leukemia, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡